Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5895894 | 0.84 | DDB1 (0.47) | DDB1CRBNGPR119HRH3KDM4E | |
| SCHEMBL16914367 | 0.77 | KDM4E (0.45) | DDB1CRBNGPR119HRH3KDM4E | |
| SCHEMBL20385872 | 0.77 | KDM4E (0.45) | DDB1CRBNGPR119HRH3KDM4E | |
| SCHEMBL31184024 | 0.77 | KDM4E (0.45) | DDB1CRBNGPR119HRH3KDM4E | |
| SCHEMBL1490070 | 0.76 | GPR119 (0.54) | GPR119KDM4EHPGDFAAH | |
| SCHEMBL29498092 | 0.76 | KDM4E (0.44) | DDB1CRBNGPR119HRH3KDM4E | |
| SCHEMBL16925178 | 0.76 | KDM4E (0.44) | DDB1CRBNGPR119HRH3KDM4E | |
| SCHEMBL5895563 | 0.75 | KDM4E (0.43) | DDB1CRBNGPR119HRH3KDM4E | |
| SCHEMBL4792848 | 0.74 | DDB1 (0.43) | DDB1CRBNGPR119HRH3KDM4E | |
| SCHEMBL5895200 | 0.74 | GPR119 (0.43) | DDB1CRBNGPR119HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396585-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396585-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | DDB1 1556/4885CRBN 247/4885GPR119 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.